Publications
Filters: First Letter Of Last Name is J [Clear All Filters]
High-Dimensional Inference for Personalized Treatment Decision." Electron J Stat 12, no. 1 (2018): 2074-2089.
" Effective SNP ranking improves the performance of eQTL mapping." Genet Epidemiol 44, no. 6 (2020): 611-619.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Efficient Signal Inclusion With Genomic Applications." J Am Stat Assoc 114, no. 528 (2019): 1787-1799.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
"CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing." Genome Biol 19, no. 1 (2018): 202.
" Interquantile Shrinkage in Regression Models." J Comput Graph Stat 22, no. 4 (2013).
"Entropy Learning for Dynamic Treatment Regimes." Stat Sin 29, no. 4 (2019): 1633-1655.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Incorporating Functional Information in Tests of Excess De Novo Mutational Load." Am J Hum Genet 97, no. 2 (2015): 272-83.
"On Estimation of Optimal Treatment Regimes For Maximizing -Year Survival Probability." J R Stat Soc Series B Stat Methodol 79, no. 4 (2017): 1165-1185.
"Interquantile Shrinkage and Variable Selection in Quantile Regression." Comput Stat Data Anal 69 (2014): 208-219.
"CODEX2: Full-spectrum copy number variation detection by high-throughput DNA sequencing. (R)., 2018.
DOUBLY ROBUST ESTIMATION OF OPTIMAL TREATMENT REGIMES FOR SURVIVAL DATA-WITH APPLICATION TO AN HIV/AIDS STUDY." Ann Appl Stat 11, no. 3 (2017): 1763-1786.
"Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application." Lifetime Data Anal 22, no. 1 (2016): 38-62.
"Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker." J Biopharm Stat 29, no. 4 (2019): 685-695.
"Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
"Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
"Type I error control for tree classification." Cancer Inform 13, no. Suppl 7 (2014): 11-8.
"Design of Phase II Non-inferiority Trials." Contemp Clin Trials Commun 7 (2017): 23-27.
"On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95.
"Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
"Statistical Methods for Conditional Survival Analysis." J Biopharm Stat 28, no. 5 (2018): 927-938.
" K-Sample comparisons using propensity analysis." Biom J 61, no. 3 (2019): 698-713.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"Randomized phase II cancer clinical tirals. Boca Raton: Chapman & Hall/CRC Press, 2013.
Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint." Med Res Arch 5, no. 7 (2017).
" Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17.
"CTD Systems (Java)., 2017.
Stratified Fisher's exact test and its sample size calculation." Biom J 56, no. 1 (2014): 129-40.
"Sample size calculation for comparing survival curves under general hypotheses testing (Fortran).., 2012.
Statistical Issues in the Design and Analysis of nCounter Projects." Cancer Inform 13, no. Suppl 7 (2014): 35-43.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"